Pembina Pipeline ( PBA ) declares C$0.735/share quarterly dividend , 3.5% increase from prior dividend of C$0.710. Payable June 30; for shareholders of record June 15; ex-div June 15. See PBA Dividend Scorecard, Yield Chart, & Dividend Growth. More on Pembina Pipeline Corporation Pembina Pipeline: Limited Upside, But Still A Buy For Yield Investors Pembina Pipeline Corporation (PPL:CA) Discusses S...
Pembina Pipeline ( PBA ) declares C$0.735/share quarterly dividend , 3.5% increase from prior dividend of C$0.710. Payable June 30; for shareholders of record June 15; ex-div June 15. See PBA Dividend Scorecard, Yield Chart, & Dividend Growth. More on Pembina Pipeline Corporation Pembina Pipeline: Limited Upside, But Still A Buy For Yield Investors Pembina Pipeline Corporation (PPL:CA) Discusses Strategic Outlook and Value Creation Initiatives in Energy Infrastructure - Slideshow Pembina Pipeline Corporation (PPL:CA) Discusses Strategic Outlook and Value Creation Initiatives in Energy Infrastructure Transcript Historical earnings data for Pembina Pipeline Corporation Dividend scorecard for Pembina Pipeline Corporation
Earnings Call Insights: PTC Therapeutics (PTCT) Q1 2026 Management View Dr. Matthew Klein said the company “had a record quarter of product revenue,” reporting total revenue of $273 million and product revenue of $226 million, and added, “we are raising our 2026 full-year product revenue guidance to $750 million to $850 million, with expected total revenue of $1.08 billion to $1.18 billion.” Dr. K...
Earnings Call Insights: PTC Therapeutics (PTCT) Q1 2026 Management View Dr. Matthew Klein said the company “had a record quarter of product revenue,” reporting total revenue of $273 million and product revenue of $226 million, and added, “we are raising our 2026 full-year product revenue guidance to $750 million to $850 million, with expected total revenue of $1.08 billion to $1.18 billion.” Dr. Klein said Sephience Q1 global revenue was $125 million, “representing 36% quarter-over-quarter growth with U.S. revenue of $112 million,” and added that as of March 31 the company had “1,244 commercial patients globally,” while in the U.S. it “surpassed the 1,500 patient start or mark in the quarter” with starts “averaging 140 per month.” Dr. Klein highlighted international acceleration, stating, “We had our first Sephience sale in Japan in late March, ahead of schedule and remain on plan to have commercial sales in up to 30 countries by year-end,” and said PTC is positioned for “the global addressable market of over 58,000 children and adults with PKU.” Eric Pauwels emphasized payer access and durability, stating “discontinuation rates remain low in the low double digits,” and that U.S. coverage policies are in place “covering over 2/3 of the U.S. population with limited restrictions and flexible criteria for reauthorization.” Pierre Gravier provided the quarter’s financial framing: “total product and royalty revenue for the first quarter was $273 million,” including “Sephience net product revenue of $125 million and DMD franchise revenue of $81 million,” and noted liquidity of “$1.89 billion as of March 31, 2026.” Outlook Management raised 2026 guidance, with Dr. Klein stating, “we are raising our 2026 full-year product revenue guidance to $750 million to $850 million, with expected total revenue of $1.08 billion to $1.18 billion.” On the trajectory behind the guidance, Dr. Klein said the company expects continued U.S. momentum, stating, “We see this robust cadence of U.S...
Afya press release ( AFYA ): Q1 GAAP EPS of R$2.85. Revenue of R$1.01B (+7.9% Y/Y). Revenue excluding acquisitions increased 7.7%, reaching R$1,008.4 million. 1Q26 Adjusted EBITDA increased 4.0% YoY, reaching R$511.4 million, with an Adjusted EBITDA Margin of 50.5%. Operating Cash Conversion ratio of 92.5% and a Free Cash Flow of R$376.0 million, with a solid cash position of R$1,332.9 million. 20...
Afya press release ( AFYA ): Q1 GAAP EPS of R$2.85. Revenue of R$1.01B (+7.9% Y/Y). Revenue excluding acquisitions increased 7.7%, reaching R$1,008.4 million. 1Q26 Adjusted EBITDA increased 4.0% YoY, reaching R$511.4 million, with an Adjusted EBITDA Margin of 50.5%. Operating Cash Conversion ratio of 92.5% and a Free Cash Flow of R$376.0 million, with a solid cash position of R$1,332.9 million. 2026 Guidance The Company is reaffirming its 2026 guidance , which assumes the successful acceptance of new students for the first semester of 2026. The guidance for 2026 is defined in the following table: Guidance for 2026 1 Revenue R$ 3,950 mn ≤ ∆ ≤ R$ 4,100 mn Adjusted EBITDA R$ 1,700 mn ≤ ∆ ≤ R$ 1,800 mn CAPEX R$ 340 mn ≤ ∆ ≤ R$ 380 mn (1) Excludes any acquisition that may be concluded after the issuance of the guidance. Click to enlarge More on Afya Afya Limited (AFYA) Q1 2026 Earnings Call Transcript Afya Limited 2026 Q1 - Results - Earnings Call Presentation Afya Limited 2025 Q4 - Results - Earnings Call Presentation Afya Non-GAAP EPS of R$2.25, revenue of R$912.99M; gives FY26 outlook Seeking Alpha’s Quant Rating on Afya
Earnings Call Insights: Gogo Inc. (GOGO) Q1 2026 Management View CEO Christopher Moore framed Q1 as a portfolio shift, saying, "The defining theme of the first quarter has been the deliberate transition of our legacy base services in air-to-ground and global satellite services into our next-generation technology portfolio." He emphasized Gogo Galileo (HDX/FDX), 5G, and GEO, adding, "We are making ...
Earnings Call Insights: Gogo Inc. (GOGO) Q1 2026 Management View CEO Christopher Moore framed Q1 as a portfolio shift, saying, "The defining theme of the first quarter has been the deliberate transition of our legacy base services in air-to-ground and global satellite services into our next-generation technology portfolio." He emphasized Gogo Galileo (HDX/FDX), 5G, and GEO, adding, "We are making steady progress on shipments, installations and early activations across both 5G and Gogo Galileo." On Galileo execution and coverage expansion, CEO Moore reported, "We shipped 92 units in the quarter, including 82 HDX and 10 FDX," and said this brought "our total number of LEO terminals shipped to 410 units since launch" across "35 commercial supplemental type certificates or STCs." He added, "We have 14 additional STCs underway to be completed in the next few quarters," and tied the ramp to OEM activity: "We expect a great ramp of shipments as important installations at multiple OEMs are expected to start in the second half of the year with Galileo becoming a line fit option." CEO Moore highlighted fleet wins and cadence, stating, "VistaJet is rolling out Gogo Galileo across its fleet with approximately 100 aircraft currently in scope as part of the broader plan to equip more than 270 aircraft globally," with installations "expanding into the U.S. with a steady cadence of roughly 1 aircraft every 9 days." He also said, "Wheels Up... is also rolling out Galileo across its 80-plus aircraft," and, "we plan to have fully rolled out the committed aircraft with NetJets Europe in the first half of 2026." On ATG, CEO Moore said, "We sold an all-time record of 511 air-to-ground units this quarter, of which 52 were 5G," and added, "we anticipate a very robust rollout throughout the rest of the year with units online ramping in late Q3 and Q4." He also stated, "we reported record C1 conversions of 254 in the first quarter," and announced, "we've secured an extension from the FCC... ...
Earnings Call Insights: Myomo, Inc. (MYO) Q1 2026 Management View "Reimbursement by CMS in a new Medicare Part B benefit category with HCPCS codes for the MyoPro has opened access to a Medicare population of tens of millions and removed the single largest historical barrier to adoption," said President, CEO & Chairman Paul Gudonis. "We're transitioning our go-to-market strategy with a distribution...
Earnings Call Insights: Myomo, Inc. (MYO) Q1 2026 Management View "Reimbursement by CMS in a new Medicare Part B benefit category with HCPCS codes for the MyoPro has opened access to a Medicare population of tens of millions and removed the single largest historical barrier to adoption," said President, CEO & Chairman Paul Gudonis. "We're transitioning our go-to-market strategy with a distribution system based on recurring patient sources from rehab hospitals and O&P providers to reduce our customer acquisition costs and to build the foundation for accelerated growth going forward," said President, CEO & Chairman Paul Gudonis. "I'm pleased to report that now more than 150 rehab facilities are now referring candidates to us" and "we announced that we've been working with Ottobock's U.S. clinical operations to certify them as MyoPro Centers of Excellence," said President, CEO & Chairman Paul Gudonis. "At the end of March, we launched a new mobile app" and "the app also eliminates the need to ship a laptop with our proprietary software to each user, reducing our MyoPro material cost by about 10%," said President, CEO & Chairman Paul Gudonis. "Our revenue for the first quarter of 2026 was $10.1 million" and "ASP in the first quarter was $58,800," said Chief Financial Officer David Henry. Outlook "We expect second quarter revenue to be in the range of $10.3 million to 10.8 million," said Chief Financial Officer David Henry. "For the full year, we are reiterating our revenue guidance in the range of $43 million to $46 million," said Chief Financial Officer David Henry. "We expect gross margin in the second quarter to be higher year-over-year, but lower sequentially due primarily to channel mix," and "we expect operating expenses to increase slightly versus the first quarter, reflecting a modest increase in advertising spending," said Chief Financial Officer Henry. "We affirm our full year operating leverage expectation to limit the growth of operating expenses in 2026 to ...
"Bloomberg: The Asia Trade" brings you everything you need to know to get ahead as the trading day begins in Asia. Bloomberg TV is live from Tokyo and Sydney with Shery Ahn and Haidi Stroud-Watts, getting insight and analysis from newsmakers and industry leaders on the biggest stories shaping global markets. (Source: Bloomberg)
"Bloomberg: The Asia Trade" brings you everything you need to know to get ahead as the trading day begins in Asia. Bloomberg TV is live from Tokyo and Sydney with Shery Ahn and Haidi Stroud-Watts, getting insight and analysis from newsmakers and industry leaders on the biggest stories shaping global markets. (Source: Bloomberg)
Atrium Mortgage Investment Corporation ( AI:CA ) declares $0.0775/share monthly dividend , in line with previous. Forward yield 7.64% Payable Aug. 12; for shareholders of record July 31; ex-div July 31. Payable Sept. 11; for shareholders of record Aug 31; ex-div Aug 31. Payable Oct. 9; for shareholders of record Sept 30; ex-div Sept 30. See AI:CA Dividend Scorecard, Yield Chart, & Dividend Growth....
Atrium Mortgage Investment Corporation ( AI:CA ) declares $0.0775/share monthly dividend , in line with previous. Forward yield 7.64% Payable Aug. 12; for shareholders of record July 31; ex-div July 31. Payable Sept. 11; for shareholders of record Aug 31; ex-div Aug 31. Payable Oct. 9; for shareholders of record Sept 30; ex-div Sept 30. See AI:CA Dividend Scorecard, Yield Chart, & Dividend Growth. More on Atrium Mortgage Investment Corporation Atrium Mortgage Investment Corporation (AI:CA) Q4 2025 Earnings Call Transcript Historical earnings data for Atrium Mortgage Investment Corporation Dividend scorecard for Atrium Mortgage Investment Corporation Financial information for Atrium Mortgage Investment Corporation
Jogyesa temple in South Korea initiated Gabi, a humanoid robot into its order this week, as it combats falling participation and interest Amid rows of colourful lanterns strung across the courtyard of Jogyesa temple in Seoul, an unusual ceremony unfolded this week: monks held a Buddhist initiation for a humanoid robot draped in saffron robe. They placed a string of 108 prayer beads around the robo...
Jogyesa temple in South Korea initiated Gabi, a humanoid robot into its order this week, as it combats falling participation and interest Amid rows of colourful lanterns strung across the courtyard of Jogyesa temple in Seoul, an unusual ceremony unfolded this week: monks held a Buddhist initiation for a humanoid robot draped in saffron robe. They placed a string of 108 prayer beads around the robot’s neck and affixed a lantern festival sticker to its mechanical arm in place of the traditional yeonbi ritual, in which burning incense is lightly pressed against the skin. Continue reading...
WELL Health Technologies press release ( WELL:CA ): Q1 Non-GAAP EPS of $0.06 in-line. Revenue of $368.3M (+25.2% Y/Y) beats by $1.92M . WELL achieved Adjusted EBITDA of $43.1 million in Q1-2026, an increase of 56% as compared to Q1-2025, representing an Adjusted EBITDA Margin (1) of 12%. Outlook: WELL is expecting strong operational performance to continue into 2026 with a greater emphasis on leve...
WELL Health Technologies press release ( WELL:CA ): Q1 Non-GAAP EPS of $0.06 in-line. Revenue of $368.3M (+25.2% Y/Y) beats by $1.92M . WELL achieved Adjusted EBITDA of $43.1 million in Q1-2026, an increase of 56% as compared to Q1-2025, representing an Adjusted EBITDA Margin (1) of 12%. Outlook: WELL is expecting strong operational performance to continue into 2026 with a greater emphasis on leveraging the depth of the product and technology offerings from the Company's Strategically Controlled Technology Platforms, WELLSTAR and HEALWELL. Management will continue to pursue its focus on optimizing operations for organic growth and profitability and is pleased to reaffirm its annual guidance for 2026, as follows: Annual revenue for 2026 is projected to be in the range of $1.55 billion to $1.65 billion vs. consensus of $1.56B Adjusted EBITDA for 2026 is projected to be in the range of $175 million to $185 million More on WELL Health Technologies WELL Health Technologies Corp. 2025 Q4 - Results - Earnings Call Presentation WELL Health Technologies Corp. (WELL:CA) Q4 2025 Earnings Call Transcript Historical earnings data for WELL Health Technologies Financial information for WELL Health Technologies
MoMo Productions/DigitalVision via Getty Images Back in January of this year, I decided to take a fresh look at Carter's ( CRI ), a rather intriguing prospect that operates as a provider of apparel and other products specifically focused on babies, toddlers, and children. At the time, I mentioned that the stock looked to be trading on the cheap. And indeed, shares were trading at very low multiple...
MoMo Productions/DigitalVision via Getty Images Back in January of this year, I decided to take a fresh look at Carter's ( CRI ), a rather intriguing prospect that operates as a provider of apparel and other products specifically focused on babies, toddlers, and children. At the time, I mentioned that the stock looked to be trading on the cheap. And indeed, shares were trading at very low multiples. However, there were issues that made it more of a ‘hold’ than a ‘buy’ at the time. This included uncertainty regarding tariffs that management had been forecasting would cost the company between $200 million and $250 million on an annualized gross basis, and declining revenue, profits, and cash flows. Until conditions stabilized, I argued, the company was not all that great a prospect. But since then, we have started to see a turnaround. Yes, the stock is up only 1.5% since that article was published. That pales in comparison to the 5.5% rise that the S&P 500 exhibited. And unfortunately, we are likely to see profitability worsen this year. However, management has been reporting growing revenue, and the latest earnings report revealed top-line and bottom line results that exceeded analysts’ expectations. Given this robust performance, I would argue that upgrading the stock to a very soft 'buy' actually makes sense here. The Picture Has Improved Author - SEC EDGAR Data On May 6th, the management team at Carter's announced financial results for the first quarter of the 2026 fiscal year for the business. Honestly, I was impressed with the data that came out. Revenue for the quarter was $681.1 million. That happened to be 8.1% above the $629.8 million that the business reported a year earlier. It was also $20.3 million greater than what analysts had hoped to see . Profitability also outperformed. Yes, earnings per share did contract from $0.43 to $0.39, taking net profits down from $15.5 million to $14.3 million. But that earnings per share figure was $0.29 greater than what...
JHVEPhoto/iStock Editorial via Getty Images Shares of Recruit Holdings ( RCRRF ) jumped as much as 6.9% on Friday in Tokyo, their biggest gain since April 1, after UBS Securities upgraded the Indeed operator’s stock to “buy” from “neutral,” arguing that fears over AI-driven disruption are “overstated.” The brokerage also raised the 12-month price target to ¥9,800 from ¥8,280, according to a Bloomb...
JHVEPhoto/iStock Editorial via Getty Images Shares of Recruit Holdings ( RCRRF ) jumped as much as 6.9% on Friday in Tokyo, their biggest gain since April 1, after UBS Securities upgraded the Indeed operator’s stock to “buy” from “neutral,” arguing that fears over AI-driven disruption are “overstated.” The brokerage also raised the 12-month price target to ¥9,800 from ¥8,280, according to a Bloomberg News report. Indeed will maintain low single digit revenue growth even after AI disruption, analysts including Yijia Zhai wrote in a report. Earnings sensitivity to drop in white-collar listings will be limited as more than two-thirds of Indeed’s paid ad revenue comes from non-white-collar roles. The stock has dropped more than 10% year to date, while the benchmark Topix has risen more than 10%. More on Recruit Holdings Co., Ltd. Recruit Holdings Co., Ltd. (RCRUY) Q3 FY2025 Earnings Call Transcript Historical earnings data for Recruit Holdings Co., Ltd. Financial information for Recruit Holdings Co., Ltd.